2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists.

[1]  G. Tomlinson,et al.  A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin‐mediated hemolysis , 2021, Transfusion.

[2]  Ping Huang,et al.  Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease , 2020, Journal of immunology research.

[3]  K. Gauvreau,et al.  Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis , 2020, Archives of Disease in Childhood.

[4]  B. McCrindle,et al.  Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products. , 2020, Blood advances.

[5]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[6]  P. Zachariah,et al.  Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. , 2020, JAMA.

[7]  L. Henderson,et al.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management , 2019, Pediatric Drugs.

[8]  K. Gauvreau,et al.  Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population , 2019, Journal of the American Heart Association.

[9]  Gaofu Zhang,et al.  Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease , 2019, BMC Pediatrics.

[10]  K. Gauvreau,et al.  Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis , 2019, Pediatrics.

[11]  Luan-Yin Chang,et al.  Outcomes of Kawasaki Disease Children With Spontaneous Defervescence Within 10 Days , 2019, Front. Pediatr..

[12]  Katherine K. Kim,et al.  The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. , 2019, Contemporary clinical trials.

[13]  L. Andreozzi,et al.  Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort , 2018, European Journal of Pediatrics.

[14]  M. Brito,et al.  Arthritis in Kawasaki disease: A poorly recognised manifestation , 2018, Journal of paediatrics and child health.

[15]  K. Waki,et al.  Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events , 2018, JAMA pediatrics.

[16]  E. Antman.  The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains. , 2018, Journal of the American College of Cardiology.

[17]  J. Newburger,et al.  Role of intravenous immunoglobulin in the treatment of Kawasaki disease , 2017, International journal of rheumatic diseases.

[18]  J. Burns.  Frequently asked questions regarding treatment of Kawasaki disease , 2017, Global cardiology science & practice.

[19]  Mei-Hwan Wu,et al.  The global epidemiology of Kawasaki disease: Review and future perspectives , 2017, Global cardiology science & practice.

[20]  B. McCrindle,et al.  Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease , 2017, Pediatrics.

[21]  Erika K Berry,et al.  High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease , 2017, The Journal of pediatrics.

[22]  K. Gauvreau,et al.  Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores , 2017, Journal of the American Heart Association.

[23]  C. Joo,et al.  Medium‐ or Higher‐Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes , 2017, The Journal of pediatrics.

[24]  G. Chodick,et al.  High-dose aspirin for Kawasaki disease: outdated myth or effective aid? , 2017, Clinical and experimental rheumatology.

[25]  J. Newburger,et al.  Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population , 2016, Journal of the American Heart Association.

[26]  H. Kil,et al.  Clinical outcome of patients with refractory Kawasaki disease based on treatment modalities , 2016, Korean journal of pediatrics.

[27]  G. Guyatt,et al.  A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. , 2016, Journal of clinical epidemiology.

[28]  Qing Zhang,et al.  Macrophage activation syndrome in Kawasaki disease: more common than we thought? , 2015, Seminars in arthritis and rheumatism.

[29]  O. Ramilo,et al.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[30]  Tomio Kobayashi,et al.  Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. , 2013, The Journal of pediatrics.

[31]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[32]  S. Taniuchi,et al.  Steroid Pulse Therapy for Children With Intravenous Immunoglobulin Therapy–Resistant Kawasaki Disease: A Prospective Study , 2013, Pediatric Cardiology.

[33]  M. El-Adawy,et al.  Preventing Coronary Artery Abnormalities: A Need for Earlier Diagnosis and Treatment of Kawasaki Disease , 2012, The Pediatric infectious disease journal.

[34]  J. Orenstein,et al.  Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study , 2012, PloS one.

[35]  T. Hara,et al.  Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial , 2012, The Lancet.

[36]  R. Uehara,et al.  Late Intravenous Immunoglobulin Treatment in Patients With Kawasaki Disease , 2012, Pediatrics.

[37]  M. Miura,et al.  Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. , 2011, Paediatrics & child health.

[38]  K. Gauvreau,et al.  Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki Disease , 2010, Pediatrics.

[39]  B. McCrindle,et al.  Kawasaki Disease at the Extremes of the Age Spectrum , 2009, Pediatrics.

[40]  J. Kanegaye,et al.  Recognition of a Kawasaki Disease Shock Syndrome , 2009, Pediatrics.

[41]  J. Newburger,et al.  Resistance to intravenous immunoglobulin in children with Kawasaki disease. , 2008, The Journal of pediatrics.

[42]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[43]  Y. Yamashiro,et al.  Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease , 2007, Archives of Disease in Childhood.

[44]  H. Yanagawa,et al.  Prevalence of coronary artery abnormality in incomplete Kawasaki disease , 2007, Pediatrics international : official journal of the Japan Pediatric Society.

[45]  Paul D. Mitchell,et al.  Coronary Artery Involvement in Children With Kawasaki Disease: Risk Factors From Analysis of Serial Normalized Measurements , 2007, Circulation.

[46]  B. McCrindle,et al.  Arthritis presenting during the acute phase of Kawasaki disease. , 2006, The Journal of pediatrics.

[47]  Kyung-Yil Lee,et al.  Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment , 2005, European Journal of Pediatrics.

[48]  J. Burns,et al.  Kawasaki Disease: A Brief History , 2000, Pediatrics.

[49]  H Yanagawa,et al.  Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. , 1998, Pediatrics.

[50]  K Hashino,et al.  Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. , 1996, Circulation.

[51]  J. Newburger,et al.  Gamma globulin re-treatment in Kawasaki disease. , 1993, The Journal of pediatrics.

[52]  M Takahashi,et al.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. , 1991, The New England journal of medicine.

[53]  J. Newburger,et al.  The treatment of Kawasaki syndrome with intravenous gamma globulin. , 1986 .

[54]  R. Rowe,et al.  Kawasaki disease: review of risk factors for coronary aneurysms. , 1986, The Journal of pediatrics.

[55]  S. Koike,et al.  Kawasaki disease: effect of treatment on coronary artery involvement. , 1979, Pediatrics.

[56]  Tomio Kobayashi,et al.  Nationwide Survey of Patients With Giant Coronary Aneurysm Secondary to Kawasaki Disease 1999-2010 in Japan. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[57]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[58]  J. Graham.  Kawasaki Disease at the Extremes of the Age Spectrum , 2010 .

[59]  Multisystem In fl ammatory Syndrome in Children , 2022 .